Astellas calls time on ex-Dynogen US facility as it tidies R&D network
This article was originally published in Scrip
Astellas is to close down a small research subsidiary in the US by the end of this year, as it looks to control costs and rationalise its corporate R&D effort.
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.